Korean Circ J.  2017 Nov;47(6):842-857. 10.4070/kcj.2017.0105.

Where Is the “Optimal” Fontan Hemodynamics?

• Ohuchi H

• KMID: 2396476
• DOI: http://doi.org/10.4070/kcj.2017.0105

Abstract

Fontan circulation is generally characterized by high central venous pressure, low cardiac output, and slightly low arterial oxygen saturation, and it is quite different from normal biventricular physiology. Therefore, when a patient with congenital heart disease is selected as a candidate for this type of circulation, the ultimate goals of therapy consist of 2 components. One is a smooth adjustment to the new circulation, and the other is long-term circulatory stabilization after adjustment. When either of these goals is not achieved, the patient is categorized as having "failed" Fontan circulation, and the prognosis is dismal. For the first goal of smooth adjustment, a lot of effort has been made to establish criteria for patient selection and intensive management immediately after the Fontan operation. For the second goal of long-term circulatory stabilization, there is limited evidence of successful strategies for long-term hemodynamic stabilization. Furthermore, there have been no data on optimal hemodynamics in Fontan circulation that could be used as a reference for patient management. Although small clinical trials and case reports are available, the results cannot be generalized to the majority of Fontan survivors. We recently reported the clinical and hemodynamic characteristics of early and late failing Fontan survivors and their association with all-cause mortality. This knowledge could provide insight into the complex Fontan pathophysiology and might help establish a management strategy for long-term hemodynamic stabilization.

Keyword

Fontan procedure; Hemodynamics; Cardiac output; Vascular resistance; Mortality

MeSH Terms

Cardiac Output
Cardiac Output, Low
Central Venous Pressure
Fontan Procedure
Heart Defects, Congenital
Hemodynamics*
Humans
Mortality
Oxygen
Patient Selection
Physiology
Prognosis
Survivors
Vascular Resistance
Oxygen

Figure

• 

  Figure 1 Fontan hemodynamics without failure. In Fontan patients, the SV supports systemic circulation. High CVP is the driving pressure of the pulmonary circulation, and the MP and RP play significant roles in pulmonary circulation. Organ PP, or the pressure difference between CVP and AOP, is low due to high CVP and low systemic pressure from diminished cardiac preload. Rs (red jagged line) appropriately increases to maintain PP, while the Rp (blue jagged line) should remain low. AOP = aortic pressure; AVV = atrioventricular valve; CVP = central venous pressure; MP = muscle pump; PA = pulmonary artery; PP = perfusion pressure; RP = respiratory pump; Rp = pulmonary artery resistance; Rs = systemic artery resistance; S/IVC = superior vena cava/inferior vena cava; SV = systemic ventricle.

• 

  Figure 2 (A) Effect of CVP on all-cause mortality in early and late Fontan survivors. High CVP has a significant adverse impact on mortality in both groups of survivors. The right upper figures show that Fontan survivors with high CVP (≥14 mmHg) have a high mortality. (B) Effect of arterial blood SaO2 on all-cause mortality in early and late Fontan survivors. Low SaO2 has a significant adverse impact on mortality in both groups of survivors. (A) and (B) are modified from those in reference 23. The right lower figures show that Fontan survivors with low SaO2 (≤93% in early survivors, ≤92% in late survivors) have high mortality. CVP = central venous pressure; SaO2 = oxygen saturation.

• 

  Figure 3 (A) Effect of end-diastolic volume of the SV (EDVI, mL/m2) on all-cause mortality in early and late Fontan survivors. Large EDVI has a significant adverse impact on mortality only in early survivors (the cutoff value was 108 mL/m2) (upper middle). However, large EDVI has no significant adverse impact on mortality in late survivors when they were divided into 2 groups based on a median EDVI value of 74 mL/m2 (upper right). (B) Effect of SV EF (%) on all-cause mortality in early and late Fontan survivors. Low EF has a significant adverse impact on mortality only in early survivors (cutoff value, 43%) (lower middle). However, low EF has no significant adverse impact on mortality in late survivors when late survivors were divided into 2 groups based on a median EF value of 53% (lower right). (A) and (B) are modified from those in reference 23). EDVI = end-diastolic systemic ventricular volume index; EF = ejection fraction; SaO2 = oxygen saturation; SV = systemic ventricle.

• 

  Figure 4 Effect of CI (L/min/m2) on all-cause mortality in early and late Fontan survivors (A). Associations between CI and all-cause mortality are U-shaped in early and late survivors with no group differences. Although a low CI tends to adversely impact all-cause mortality (B) in early survivors, a high CI has a significantly adverse impact on mortality in late survivors (C). (A) is modified from reference 23). CI = cardiac index.

• 

  Figure 5 Effects of pulmonary (A) and systemic (B) arterial resistance on all-cause mortality in early and late Fontan survivors. Although no significant associations between these variables and all-cause mortality were identified, the associations are unique and U-shaped in the late survivors. For systemic artery resistance, low resistance tended to have an adverse impact on mortality (HR, 0.94; 95% CI, 0.87–1.00; p=0.060). 95% CI = 95% confidence interval; HR = hazard ratio.

• 

  Figure 6 Traditional failing Fontan hemodynamics (high CVP with low output) and possible therapeutic options. For systemic ventricular systolic dysfunction, conventional anti-HF strategies might be successful. In addition, pulmonary artery dilators could also be effective. For AVV impairment, surgical options should be considered. ACEI = angiotensin converting enzyme inhibitor; AOP = aortic pressure; ARB = angiotensin II receptor blocker; AVV = atrioventricular valve; AVVP/R = atrioventricular valvuloplasty or replacement; CRT = cardiac resynchronization therapy; CVP = central venous pressure; EM = coil embolization to collateral vessels; ETB = endothelin receptor blocker; HF = heart failure; HOT = home oxygen therapy; IVN = catheter intervention; LAP: functional left atrial pressure; MP = muscle pump; NO = nitric oxide; PDE5I = phosphodiesterase 5 inhibitor; PGI2 = prostaglandin I2; PTA = percutaneous transluminal angioplasty; RP = respiratory pump; Rp = pulmonary artery resistance; Rs = systemic artery resistance; S/IVC = superior vena cava/inferior vena cava.

• 

  Figure 7 Newly recognized failing Fontan hemodynamics (high CVP with high output) and possible therapeutic options. For this failing Fontan hemodynamic phenotype, traditional therapeutic approaches might be questionable and can even be harmful. Inappropriately low Rs requires vasoconstrictors, such as alpha 1 receptor agonists (midodrine). For coexistent hypoxia, oxygen inhalation might be effective. ACEI/ARBs = angiotensin converting enzyme inhibitors or angiotensin receptor blockers; AVV = atrioventricular valve; CRT = cardiac resynchronization therapy; CVP = central venous pressure; EM = coil embolization to collateral vessels; ETB = endothelin receptor blocker; HOT = home oxygen therapy; MP = muscle pump; NO = nitric oxide; PA = pulmonary artery; PDE5I = phosphodiesterase 5 inhibitor; PGI2 = prostaglandin I2; PP = perfusion pressure; PTA = percutaneous transluminal angioplasty; RP = respiratory pump; Rs = systemic artery resistance; S/IVC = superior vena cava/inferior vena cava.

Reference

1. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971; 26:240–248.

2. d’Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007; 116:I157–I164.

3. Ohuchi H, Kagisaki K, Miyazaki A, et al. Impact of the evolution of the Fontan operation on early and late mortality: a single-center experience of 405 patients over 3 decades. Ann Thorac Surg. 2011; 92:1457–1466.

4. Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008; 117:85–92.

5. Diller GP, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. Circulation. 2015; 132:2118–2125.

6. Quinton E, Nightingale P, Hudsmith L, et al. Prevalence of atrial tachyarrhythmia in adults after Fontan operation. Heart. 2015; 101:1672–1677.

7. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol. 2014; 64:54–62.

8. Ohuchi H, Yasuda K, Miyazaki A, et al. Haemodynamic characteristics before and after the onset of protein losing enteropathy in patients after the Fontan operation. Eur J Cardiothorac Surg. 2013; 43:e49–e57.

9. Moore JW, Kirby WC, Madden WA, Gaither NS. Development of pulmonary arteriovenous malformations after modified Fontan operations. J Thorac Cardiovasc Surg. 1989; 98:1045–1050.

10. Ohuchi H, Yasuda K, Miyazaki A, et al. Prevalence and predictors of haemostatic complications in 412 Fontan patients: their relation to anticoagulation and haemodynamics. Eur J Cardiothorac Surg. 2015; 47:511–519.

11. Egbe AC, Connolly HM, Niaz T, et al. Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation. Am Heart J. 2017; 183:10–17.

12. Ohuchi H, Yasuda K, Miyazaki A, et al. Comparison of prognostic variables in children and adults with Fontan circulation. Int J Cardiol. 2014; 173:277–283.

13. Assenza GE, Graham DA, Landzberg MJ, et al. MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery. Heart. 2013; 99:491–496.

14. Pundi K, Pundi KN, Kamath PS, et al. Liver disease in patients after the Fontan operation. Am J Cardiol. 2016; 117:456–460.

15. Asrani SK, Warnes CA, Kamath PS. Hepatocellular carcinoma after the Fontan procedure. N Engl J Med. 2013; 368:1756–1757.

16. Ohuchi H. Adult patients with Fontan circulation: what we know and how to manage adults with Fontan circulation? J Cardiol. 2016; 68:181–189.

17. Ohuchi H, Ohashi H, Takasugi H, Yamada O, Yagihara T, Echigo S. Restrictive ventilatory impairment and arterial oxygenation characterize rest and exercise ventilation in patients after Fontan operation. Pediatr Cardiol. 2004; 25:513–521.

18. Ohuchi H, Yasuda K, Hasegawa S, et al. Influence of ventricular morphology on aerobic exercise capacity in patients after the Fontan operation. J Am Coll Cardiol. 2001; 37:1967–1974.

19. Heinemann M, Breuer J, Steger V, Steil E, Sieverding L, Ziemer G. Incidence and impact of systemic venous collateral development after Glenn and Fontan procedures. Thorac Cardiovasc Surg. 2001; 49:172–178.

20. Levine TB, Levine AB. Regional blood flow supply and demand in heart failure. Am Heart J. 1990; 120:1547–1551.

21. Drexler H. Reduced exercise tolerance in chronic heart failure and its relationship to neurohumoral factors. Eur Heart J. 1991; 12:Suppl C. 21–28.

22. Latus H, Gummel K, Diederichs T, et al. Aortopulmonary collateral flow is related to pulmonary artery size and affects ventricular dimensions in patients after the Fontan procedure. PLoS One. 2013; 8:e81684.

23. Ohuchi H, Miyazaki A, Negishi J, et al. Hemodynamic determinants of mortality after Fontan operation. Am Heart J. 2017; 189:9–18.

24. Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. Circulation. 1996; 94:690–697.

25. Deal BJ, Jacobs ML. Management of the failing Fontan circulation. Heart. 2012; 98:1098–1104.

26. De Rita F, Crossland D, Griselli M, Hasan A. Management of the failing Fontan. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2015; 18:2–6.

27. Mori M, Aguirre AJ, Elder RW, et al. Beyond a broken heart: circulatory dysfunction in the failing Fontan. Pediatr Cardiol. 2014; 35:569–579.

28. Mizuno M, Ohuchi H, Matsuyama TA, Miyazaki A, Ishibashi-Ueda H, Yamada O. Diverse multi-organ histopathologic changes in a failed Fontan patient. Pediatr Int. 2016; 58:1061–1065.

29. Ohuchi H, Negishi J, Hayama Y, Miyazaki A, Shiraishi I, Ichikawa H. Renal resistive index reflects Fontan pathophysiology and predicts mortality. [Epub ahead of print]. Heart. 2017.

30. Ohuchi H, Miyamoto Y, Yamamoto M, et al. High prevalence of abnormal glucose metabolism in young adult patients with complex congenital heart disease. Am Heart J. 2009; 158:30–39.

31. Avitabile CM, Leonard MB, Zemel BS, et al. Lean mass deficits, vitamin D status and exercise capacity in children and young adults after Fontan palliation. Heart. 2014; 100:1702–1707.

32. Avitabile CM, Goldberg DJ, Zemel BS, et al. Deficits in bone density and structure in children and young adults following Fontan palliation. Bone. 2015; 77:12–16.

33. Book WM, Gerardin J, Saraf A, Marie Valente A, Rodriguez F 3rd. Clinical phenotypes of Fontan failure: implications for management. Congenit Heart Dis. 2016; 11:296–308.

34. Hebson CL, McCabe NM, Elder RW, et al. Hemodynamic phenotype of the failing Fontan in an adult population. Am J Cardiol. 2013; 112:1943–1947.

35. Mori M, Hebson C, Shioda K, et al. Catheter-measured hemodynamics of adult Fontan circulation: associations with adverse event and end-organ dysfunctions. Congenit Heart Dis. 2016; 11:589–597.

36. Mitchell MB, Campbell DN, Ivy D, et al. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg. 2004; 128:693–702.

37. Henaine R, Vergnat M, Bacha EA, et al. Effects of lack of pulsatility on pulmonary endothelial function in the Fontan circulation. J Thorac Cardiovasc Surg. 2013; 146:522–529.

38. Ohuchi H, Ono S, Tanabe Y, et al. Long-term serial aerobic exercise capacity and hemodynamic properties in clinically and hemodynamically good, “excellent”, Fontan survivors. Circ J. 2012; 76:195–203.

39. Iwakiri Y, Tsai MH, McCabe TJ, et al. Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. Am J Physiol Heart Circ Physiol. 2002; 282:H2084–H2090.

40. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006; 43:S121–S131.

41. Song D, Liu H, Sharkey KA, Lee SS. Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology. 2002; 35:159–166.

42. Waypa GB, Schumacker PT. Hypoxia-induced changes in pulmonary and systemic vascular resistance: where is the O2 sensor? Respir Physiol Neurobiol. 2010; 174:201–211.

43. Rychik J, Veldtman G, Rand E, et al. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol. 2012; 33:1001–1012.

44. Carins TA, Shi WY, Iyengar AJ, et al. Long-term outcomes after first-onset arrhythmia in Fontan physiology. J Thorac Cardiovasc Surg. 2016; 152:1355–1363.e1.

45. Pundi KN, Pundi KN, Johnson JN, et al. Sudden cardiac death and late arrhythmias after the Fontan operation. Congenit Heart Dis. 2017; 12:17–23.

46. Li D, Fan Q, Hirata Y, Ono M, An Q. Arrhythmias after Fontan operation with intra-atrial lateral tunnel versus extra-cardiac conduit: a systematic review and meta-analysis. Pediatr Cardiol. 2017; 38:873–880.

47. Allen KY, Downing TE, Glatz AC, et al. Effect of Fontan-associated morbidities on survival with intact Fontan circulation. Am J Cardiol. 2017; 119:1866–1871.

48. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. Circ J. 2012; 76:268–277.

49. Wojnowich K, Korabathina R. Heart failure update: outpatient management. FP Essent. 2016; 442:18–25.

50. Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med. 2014; 370:1694–1701.

51. Enomoto Y, Aoki M, Nakamura Y, Hagino I, Fujiwara T, Nakajima H. Successful Fontan completion after cardiac resynchronization therapy. Circulation. 2012; 125:e655–e658.

52. Takeuchi D, Asagai S, Ishihara K, Nakanishi T. Successful Fontan conversion combined with cardiac resynchronization therapy for a case of failing Fontan circulation with ventricular dysfunction. Eur J Cardiothorac Surg. 2014; 46:913–915.

53. Honjo O, Atlin CR, Mertens L, et al. Atrioventricular valve repair in patients with functional single-ventricle physiology: impact of ventricular and valve function and morphology on survival and reintervention. J Thorac Cardiovasc Surg. 2011; 142:326–335.e2.

54. King G, Gentles TL, Winlaw DS, et al. Common atrioventricular valve failure during single ventricle palliation. Eur J Cardiothorac Surg. 2017; 51:1037–1043.

55. Agnoletti G, Gala S, Ferroni F, et al. Endothelin inhibitors lower pulmonary vascular resistance and improve functional capacity in patients with Fontan circulation. J Thorac Cardiovasc Surg. 2017; 153:1468–1475.

56. Tabarsi N, Guan M, Simmonds J, et al. Meta-analysis of the effectiveness of heart transplantation in patients with a failing Fontan. Am J Cardiol. 2017; 119:1269–1274.

57. Matsuda H, Ichikawa H, Ueno T, Sawa Y. Heart transplantation for adults with congenital heart disease: current status and future prospects. Gen Thorac Cardiovasc Surg. 2017; 65:309–320.

58. de Mattos ÁZ, de Mattos AA, Méndez-Sánchez N. Hepatorenal syndrome: current concepts related to diagnosis and management. Ann Hepatol. 2016; 15:474–481.

59. Ruiz-del-햞bol L. Serradilla R. Cirrhotic cardiomyopathy. World J Gastroenterol. 2015; 21:11502–11521.

60. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg. 2006; 82:e39–e40.

61. Bhagirath KM, Tam JW. Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation. Ann Thorac Surg. 2007; 84:2110–2112.

62. Hoashi T, Ichikawa H, Ueno T, Kogaki S, Sawa Y. Steroid pulse therapy for protein-losing enteropathy after the Fontan operation. Congenit Heart Dis. 2009; 4:284–287.

63. Straver B, Wagenaar LJ, Blom NA, et al. Percutaneous tricuspid valve implantation in a Fontan patient with congestive heart failure and protein-losing enteropathy. Circ Cardiovasc Interv. 2011; 4:112–113.

64. John AS, Driscoll DJ, Warnes CA, Phillips SD, Cetta F. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2011; 92:1451–1456.

65. Okano S, Sugimoto M, Takase M, Iseki K, Kajihama A, Azuma H. Effectiveness of high-dose spironolactone therapy in a patient with recurrent protein-losing enteropathy after the Fontan procedure. Intern Med. 2016; 55:1611–1614.

66. António M, Gordo A, Pereira C, Pinto F, Fragata I, Fragata J. Thoracic duct decompression for protein-losing enteropathy in failing Fontan circulation. Ann Thorac Surg. 2016; 101:2370–2373.

67. Friedland-Little JM, Gajarski RJ, Schumacher KR. Dopamine as a potential rescue therapy for refractory protein-losing enteropathy in Fontan-palliated patients. Pediatr Transplant. 2017; 21:e12925.

68. Wakeham MK, Van Bergen AH, Torero LE, Akhter J. Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient. Pediatr Crit Care Med. 2005; 6:76–78.

69. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant. 2005; 24:1174–1176.

70. Heath L, Ling S, Racz J, et al. Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. Pediatr Cardiol. 2011; 32:1182–1189.

71. Dori Y, Keller MS, Rome JJ, et al. Percutaneous lymphatic embolization of abnormal pulmonary lymphatic flow as treatment of plastic bronchitis in patients with congenital heart disease. Circulation. 2016; 133:1160–1170.

72. Opocher F, Varnier M, Sanders SP, et al. Effects of aerobic exercise training in children after the Fontan operation. Am J Cardiol. 2005; 95:150–152.

73. Brassard P, Poirier P, Martin J, et al. Impact of exercise training on muscle function and ergoreflex in Fontan patients: a pilot study. Int J Cardiol. 2006; 107:85–94.

74. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008; 29:1681–1687.

75. Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011; 123:1185–1193.

76. Schuuring MJ, Vis JC, van Dijk AP, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013; 15:690–698.

77. Cordina RL, O'Meagher S, Karmali A, et al. Resistance training improves cardiac output, exercise capacity and tolerance to positive airway pressure in Fontan physiology. Int J Cardiol. 2013; 168:780–788.

78. Rhodes J, Ubeda-Tikkanen A, Clair M, et al. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013; 168:2435–2440.

79. Van De Bruaene A, La Gerche A, Claessen G, et al. Sildenafil improves exercise hemodynamics in Fontan patients. Circ Cardiovasc Imaging. 2014; 7:265–273.

80. Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation. 2014; 130:2021–2030.